Evidence map›Paper›PMID 25393309›Full record

ArticlePloS one2014

BDC12-4.1 T-cell receptor transgenic insulin-specific CD4 T cells are resistant to in vitro differentiation into functional Foxp3+ T regulatory cells.

Ghanashyam Sarikonda, Georgia Fousteri, Sowbarnika Sachithanantham, Jacqueline F Miller, Amy Dave, Therese Juntti, Ken T Coppieters, Matthias von Herrath

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ghanashyam SarikondaDiabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Georgia FousteriDiabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Sowbarnika SachithananthamDiabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Jacqueline F MillerDiabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Amy DaveDiabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Therese JunttiDiabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Ken T CoppietersType 1 Diabetes R&D center, Novo Nordisk Inc., Seattle, Washington, USA.
Matthias von HerrathDiabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA; Type 1 Diabetes R&D center, Novo Nordisk Inc., Seattle, Washington, USA.
La Jolla Institute for Immunology · USNovo Nordisk (United States) · US

Funding

Virginia Mason/UCHSC Autoimmune Prevention CenterU19AI050864 · NIAID · UNIVERSITY OF COLORADO DENVER · PI EISENBARTH, GEORGE S · 2001 to 2011
$29.2M
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 DiabetesU01DK078013 · NIDDK · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI VON HERRATH, MATTHIAS G. · 2006 to 2011
$2.7M
NIAID NIH HHS 5U19AI050864-08NIAID NIH HHS U19 AI050864NIDDK NIH HHS DK078013NIDDK NIH HHS U01 DK078013
6 · The paper itself

Abstract

The infusion of ex vivo-expanded autologous T regulatory (Treg) cells is potentially an effective immunotherapeutic strategy against graft-versus-host disease (GvHD) and several autoimmune diseases, such as type 1 diabetes (T1D). However, in vitro differentiation of antigen-specific T cells into functional and stable Treg (iTreg) cells has proved challenging. As insulin is the major autoantigen leading to T1D, we tested the capacity of insulin-specific T-cell receptor (TCR) transgenic CD4(+) T cells of the BDC12-4.1 clone to convert into Foxp3(+) iTreg cells. We found that in vitro polarization toward Foxp3(+) iTreg was effective with a majority (>70%) of expanded cells expressing Foxp3. However, adoptive transfer of Foxp3(+) BDC12-4.1 cells did not prevent diabetes onset in immunocompetent NOD mice. Thus, in vitro polarization of insulin-specific BDC12-4.1 TCR transgenic CD4(+) T cells toward Foxp3+ cells did not provide dominant tolerance in recipient mice. These results highlight the disconnect between an in vitro acquired Foxp3(+) cell phenotype and its associated in vivo regulatory potential.

Indexed as

Adoptive TransferAnimalsAutoantigensCD4-Positive T-LymphocytesCell DifferentiationDiabetes Mellitus, Type 1Forkhead Transcription FactorsGene ExpressionInsulinMiceMice, Inbred NODMice, TransgenicReceptors, Antigen, T-CellT-Lymphocytes, RegulatoryAutoantigensForkhead Transcription FactorsFoxp3 protein, mouseInsulinReceptors, Antigen, T-Cell

Identifiers

PMID25393309
PMCPMC4231041
OpenAlexW2064211331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.